User profiles for D. G. Downey
 | Damian DowneyProfessor, Queen's University Belfast Verified email at qub.ac.uk Cited by 5600 |
Neutrophils in cystic fibrosis
Lung injury in cystic fibrosis is caused by recurrent airway infection and inflammation.
Neutrophils are important in combating these infections but are also the predominate cells …
Neutrophils are important in combating these infections but are also the predominate cells …
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double …
Background Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct
the basic defect caused by CFTR mutations. Improvements in health outcomes have been …
the basic defect caused by CFTR mutations. Improvements in health outcomes have been …
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene
in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a …
in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a …
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
…, G Retsch-Bogart, DG Downey - The Lancet …, 2023 - thelancet.com
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane
conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally …
conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally …
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week …
Background Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe …
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe …
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del …
Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance
regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated …
regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated …
[HTML][HTML] The effect of CFTR modulators on airway infection in cystic fibrosis
The advent of Cystic fibrosis transmembrane receptor (CFTR) modulators in 2012 was a critical
event in the history of cystic fibrosis (CF) treatment. Unlike traditional therapies that target …
event in the history of cystic fibrosis (CF) treatment. Unlike traditional therapies that target …
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
Cystic fibrosis is a multiorgan disease caused by impaired function of the cystic fibrosis
transmembrane conductance regulator (CFTR). Since the introduction of the CFTR modulator …
transmembrane conductance regulator (CFTR). Since the introduction of the CFTR modulator …
[HTML][HTML] Airway inflammation and host responses in the era of CFTR modulators
The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a
new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in …
new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in …
Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis
Objectives Cystic fibrosis (CF) lung disease is characterised by mucus stasis, chronic infection
and inflammation, causing progressive structural lung disease and eventual respiratory …
and inflammation, causing progressive structural lung disease and eventual respiratory …